The convergence of genomic medicine and translational omics in transforming breast cancer patient care.
作者信息
Wu Sulin, Zheng Yonglan, Olopade Olufunmilayo I
机构信息
Section of Hematology and Oncology, Department of Medicine and.
Center for Clinical Cancer Genetics & Global Health, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
出版信息
J Clin Invest. 2024 Nov 1;134(21):e187520. doi: 10.1172/JCI187520.
Abstract
摘要
相似文献
1
The convergence of genomic medicine and translational omics in transforming breast cancer patient care.基因组医学与转化组学在改变乳腺癌患者护理方面的融合。
J Clin Invest. 2024 Nov 1;134(21):e187520. doi: 10.1172/JCI187520.
2
MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.MOBCdb：一个综合的乳腺癌多组学数据库，用于精准医学。
Breast Cancer Res Treat. 2018 Jun;169(3):625-632. doi: 10.1007/s10549-018-4708-z. Epub 2018 Feb 10.
3
Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.基于乳腺癌元维度组学数据间的相互作用预测删失生存数据。
J Biomed Inform. 2015 Aug;56:220-8. doi: 10.1016/j.jbi.2015.05.019. Epub 2015 Jun 3.
4
Robust automatic breast cancer staging using a combination of functional genomics and image-omics.使用功能基因组学和影像组学相结合的方法进行稳健的乳腺癌自动分期。
Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:7226-9. doi: 10.1109/EMBC.2015.7320059.
5
Omics sciences and precision medicine in breast and ovarian cancer.肿瘤组学与精准医学在乳腺癌和卵巢癌中的应用
Clin Ter. 2023 Nov-Dec;174(Suppl 2(6)):104-118. doi: 10.7417/CT.2023.2477.
6
Advancing personalized medicine: Integrating statistical algorithms with omics and nano-omics for enhanced diagnostic accuracy and treatment efficacy.推进个性化医学：将统计算法与组学和纳米组学相结合，提高诊断准确性和治疗效果。
Biochim Biophys Acta Mol Basis Dis. 2024 Oct;1870(7):167339. doi: 10.1016/j.bbadis.2024.167339. Epub 2024 Jul 8.
7
A guide to multi-omics data collection and integration for translational medicine.转化医学多组学数据收集与整合指南。
Comput Struct Biotechnol J. 2022 Dec 1;21:134-149. doi: 10.1016/j.csbj.2022.11.050. eCollection 2023.
8
crcTRP: a translational research platform for colorectal cancer.CRC-TRP：结直肠癌的转化研究平台。
Comput Math Methods Med. 2013;2013:930362. doi: 10.1155/2013/930362. Epub 2013 Jan 29.
9
404-error "Disease not found": Unleashing the translational potential of -omics approaches beyond traditional disease classification in heart failure research.404 错误“未发现疾病”：在心力衰竭研究中超越传统疾病分类，释放组学方法的转化潜力。
Eur J Heart Fail. 2024 Jun;26(6):1313-1323. doi: 10.1002/ejhf.3268. Epub 2024 May 13.
10
A Translational Pipeline for Overall Survival Prediction of Breast Cancer Patients by Decision-Level Integration of Multi-Omics Data.一种通过多组学数据的决策级整合对乳腺癌患者总生存期进行预测的转化流程。
Proceedings (IEEE Int Conf Bioinformatics Biomed). 2019 Nov;2019:1573-1580. doi: 10.1109/bibm47256.2019.8983243. Epub 2020 Feb 6.
引用本文的文献
1
Cancer complexity: why we need a novel cancer research strategy.癌症复杂性：为何我们需要一种全新的癌症研究策略。
Front Oncol. 2025 Aug 1;15:1624467. doi: 10.3389/fonc.2025.1624467. eCollection 2025.
2
Nanoformulations Downregulating METTL16 Combined with mRNA Tumor Vaccines Suppress Triple-Negative Breast Cancer and Prevent Metastasis.下调METTL16的纳米制剂与mRNA肿瘤疫苗联合使用可抑制三阴性乳腺癌并预防转移。
Int J Nanomedicine. 2025 Jul 11;20:8951-8966. doi: 10.2147/IJN.S520329. eCollection 2025.
本文引用的文献
1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.在晚期或转移性 HR+/HER2-和三阴性乳腺癌中应用德曲妥珠单抗偶联物：TROPION-PanTumor01 研究的 I 期结果。
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.基于风险的女性乳腺癌筛查综合遗传风险评估。
J Clin Oncol. 2024 May 1;42(13):1477-1487. doi: 10.1200/JCO.23.00295. Epub 2024 Feb 29.
3
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗-德鲁替康与医生选择的治疗方案用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌患者（DESTINY-Breast02）：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20.
4
Polygenic risk scores and breast cancer risk prediction.多基因风险评分与乳腺癌风险预测。
Breast. 2023 Feb;67:71-77. doi: 10.1016/j.breast.2023.01.003. Epub 2023 Jan 10.
5
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.《2022 年世卫组织神经内分泌肿瘤分类概述》。
Endocr Pathol. 2022 Mar;33(1):115-154. doi: 10.1007/s12022-022-09708-2. Epub 2022 Mar 16.
6
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
7
Multi-omic machine learning predictor of breast cancer therapy response.乳腺癌治疗反应的多组学机器学习预测器。
Nature. 2022 Jan;601(7894):623-629. doi: 10.1038/s41586-021-04278-5. Epub 2021 Dec 7.
8
Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes.对尼日利亚乳腺癌患者的全基因组分析揭示了种族驱动的体细胞进化和不同的基因组亚型。
Nat Commun. 2021 Nov 26;12(1):6946. doi: 10.1038/s41467-021-27079-w.
9
The impact of site-specific digital histology signatures on deep learning model accuracy and bias.基于组织特异性数字组织学特征对深度学习模型准确性和偏差的影响。
Nat Commun. 2021 Jul 20;12(1):4423. doi: 10.1038/s41467-021-24698-1.
10
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.奥拉帕利辅助治疗 - 或 - 突变型乳腺癌患者。
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
Zotero 插件